Publications

• April 1, 2014
  

  Advancing the Portfolio of Tuberculosis Diagnostics, Drugs, Biomarkers, and Vaccines

  Zumla AI, Schito M, Maeurer M. Advancing the Portfolio of Tuberculosis Diagnostics, Drugs, Biomarkers, and Vaccines. The Lancet Infectious Diseases. 2014 Apr;14(4):267–9.

• April 1, 2014
  

  Operationalizing Hippocampal Volume as an Enrichment Biomarker for Amnestic Mild Cognitive Impairment Trials: Effect of Algorithm, Test-Retest Variability, and Cut Point on Trial Cost, Duration, and Sample Size

• April 1, 2014
  

  New Antituberculosis Drugs, Regimens, and Adjunct Therapies: Needs, Advances, and Future Prospects

  Zumla AI, Gillespie SH, Hoelscher M, Philips PPJ, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ. New Antituberculosis Drugs, Regimens, and Adjunct Therapies: Needs, Advances, and Future Prospects. The Lancet Infectious Diseases. 2014 Apr;14(4):327–40.

• April 1, 2014
  

  Totally-Drug-Resistant Tuberculosis: Hype versus Hope

  Maeurer M, Schito M, Zumla A. Totally-Drug-Resistant Tuberculosis: Hype versus Hope. The Lancet Respiratory Medicine. 2014 Apr;2(4):256–7.

• April 1, 2014
  

  Progress in Tuberculosis Vaccine Development and Host-Directed Therapies–a State of the Art Review

  Kaufmann SHE, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI, Maeurer M. Progress in Tuberculosis Vaccine Development and Host-Directed Therapies–a State of the Art Review. The Lancet Respiratory Medicine. 2014 Apr;2(4):301–20.